@misc{indiciae41abfc9f15ed,
  title = {The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.},
  author = {Kim, D. and Lee, S.-H. and Choi, Y.-H. and Kang, S.-M. and Lee, M.-G. L. and Hong, S.-B. and Perouzel, E. and Debin, A.},
  year = {2023},
  doi = {10.1101/2023.10.25.564097},
  url = {https://www.biorxiv.org/content/10.1101/2023.10.25.564097v1},
  note = {Source identifier: 10.1101/2023.10.25.564097}
}